Sutro Biopharma, Inc. (STRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. on February 10, 2026, reporting events occurring on February 9, 2026. The Company is a biopharmaceutical firm focused on research, clinical, and process development of product candidates.
Key Financial Metrics and Capital Resources
- Offering Size: 7,868,383 shares of common stock.
- Offering Price: $13.98 per share.
- Gross Proceeds: Approximately $110.0 million (before underwriting discounts and expenses).
- Existing Liquidity: Cash, cash equivalents, and marketable securities as of January 1, 2026, were approximately $141.4 million (derived from total capital resources of $251.4 million less $110.0 million proceeds).
- Total Capital Resources: Approximately $251.4 million post-offering.
- Cash Runway: Estimated to fund operating expenses and capital expenditures into the second quarter of 2028.
Material Changes and Transactions
The primary material change is the entry into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC for a public offering of common stock. The transaction is expected to close on February 11, 2026, subject to customary conditions. This represents a significant increase in the Company's liquidity position compared to the start of the year.
Guidance, Outlook, and Risks
Use of Proceeds: Net proceeds will be used for general corporate purposes, including funding research, clinical and process development, manufacturing, working capital, potential acquisitions, and capital expenditures.
Outlook: Management estimates the combined capital resources will sustain operations into Q2 2028.
Risks: The filing contains forward-looking statements regarding cash estimates, net proceeds, and runway. Actual results may differ due to risks identified in the Company's Form 10-Q for the period ended September 30, 2025, and the prospectus supplement. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and commissions.
- Review the attached Corporate Presentation (Exhibit 99.1) for updated clinical trial timelines and strategic priorities.
- Confirm the exact amount of cash, cash equivalents, and marketable securities as of the most recent balance sheet date to validate the $141.4 million pre-offering liquidity estimate.
- Monitor the prospectus supplement for specific details on underwriting fees and lock-up provisions.